Revive Therapeutics Announces
Published Research Results on Bucillamine as Potential Inhibitor of
SARS-CoV-2 Infection Delta Variant
TORONTO, November 16, 2021 -- InvestorsHub NewsWire -- Revive
Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences
company focused on the research and development of therapeutics for
medical needs and rare disorders, announced today a research study,
titled "Thiol drugs decrease SARS-CoV-2 lung injury in
vivo and disrupt SARS-CoV-2 spike complex binding to ACE2 in
vitro" from the
University of California, San Francisco, showing that potent thiol
drugs, like Bucillamine, inhibit SARS-CoV-2 infection in vitro,
specifically the Delta variant (B.1.617.2), which is now globally
dominant, and also reducing SARS-CoV-2-related lung injury in vivo
and providing strong rationale for trials of systemically delivered
thiol drugs as COVID-19 treatments. In addition to its
anti-oxidant and anti-inflammatory properties that could limit lung
injury in COVID-19, thiol drugs have promising antiviral
effects.
The Company is currently exploring oral Bucillamine in a
Phase 3 clinical study to treat mild-to-moderate COVID-19, and
based on the published paper and the University work, the Company
will also seek to develop a reformulated version of Bucillamine as
a potential treatment for severe COVID-19 disease and related
infectious diseases.
"We are excited to see another published paper supporting
potent thiol drugs, like Bucillamine, for COVID-19, including the
Delta variant, as we continue in our Phase 3 clinical study with
Bucillamine to treat mild-to-moderate COVID-19. We are also gathering new
scientific evidence to support Bucillamine's potential for severe
COVID-19," said Michael Frank, CEO of
the Company.
The research
work was funded by an intramural grant from UCSF -The COVID-19
Rapid Response Pilot Grant
Initiative Funding Collaborative (JVF), a research grant from
Revive Therapeutics (JVF) and
the US National Institutes of Health P01 HL128191 (JVF).
For a copy of
the research paper, visit https://www.biorxiv.org/content/10.1101/2020.12.08.415505v2.full.pdf
The Company is not making
any express or implied claims that its product has the ability to
eliminate or cure COVID-19 (SARS-2 Coronavirus) at this
time.
About Revive Therapeutics
Ltd.
Revive is a life sciences company focused on the research and
development of therapeutics for infectious diseases and rare
disorders, and it is prioritizing drug development efforts to take
advantage of several regulatory incentives awarded by the FDA such
as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric
Disease designations. Currently, the Company is exploring the use
of Bucillamine for the potential treatment of infectious diseases,
with an initial focus on severe influenza and COVID-19. With its
acquisition of Psilocin Pharma Corp., Revive is advancing the
development of Psilocybin-based therapeutics in various diseases
and disorders. Revive's cannabinoid pharmaceutical portfolio
focuses on rare inflammatory diseases and the Company was granted
FDA orphan drug status designation for the use of Cannabidiol (CBD)
to treat autoimmune hepatitis (liver disease) and to treat ischemia
and reperfusion injury from organ transplantation.
For more
information, visit www.ReviveThera.com.
For more information, please contact:
Michael Frank
Chief Executive Officer
Revive Therapeutics Ltd.
Tel: 1 888 901 0036
Email: mfrank@revivethera.com
Website: www.revivethera.com
Neither the
Canadian Securities Exchange nor its Regulation Services Provider
has reviewed or accepts responsibility for the adequacy or accuracy
of this release.
Cautionary
Statement
This
press release contains 'forward-looking information' within the
meaning of applicable Canadian securities legislation. These
statements relate to future events or future performance. The use
of any of the words "could", "intend", "expect", "believe", "will",
"projected", "estimated" and similar expressions and statements
relating to matters that are not historical facts are intended to
identify forward-looking information and are based on Revive's
current belief or assumptions as to the outcome and timing of such
future events. Forward looking information in this press release
includes information with respect to the Company's cannabinoids,
psychedelics and infectious diseases programs. Forward-looking
information is based on reasonable assumptions that have been made
by Revive at the date of the information and is subject to known
and unknown risks, uncertainties, and other factors that may cause
actual results or events to differ materially from those
anticipated in the forward-looking information. Given these risks,
uncertainties and assumptions, you should not unduly rely on these
forward-looking statements. The forward-looking information
contained in this press release is made as of the date hereof, and
Revive is not obligated to update or revise any forward-looking
information, whether as a result of new information, future events
or otherwise, except as required by applicable securities laws. The
foregoing statements expressly qualify any forward-looking
information contained herein. Reference is made to the risk factors
disclosed under the heading "Risk Factors" in the Company's annual
MD&A for the fiscal year ended June 30, 2021, which has been
filed on SEDAR and is available under the Company's profile
at www.sedar.com.